XASX
PME
Market cap21bUSD
Jul 08, Last price
314.20AUD
1D
1.36%
1Q
66.87%
Jan 2017
6,445.83%
IPO
22,834.31%
Name
Pro Medicus Ltd
Chart & Performance
Profile
Pro Medicus Limited engages in the development and supply of healthcare imaging software and services to hospitals, diagnostic imaging groups, and other related health entities in Australia, North America, and Europe. The company offers radiology information systems (RIS), a proprietary medical software for practice management, training, installation, professional services, and after-sale support and service products; and Promedicus.net, an e-health platform. It also provides healthcare imaging software that provides radiologists and clinicians with visualization capability for viewing 2-D, 3-D, and 4-D medical images, as well as picture archive and communication system (PACS)/digital imaging software; and integration products. In addition, the company offers Visage Ease Pro, a mobile application that provides users the ability to interpret various diagnostic imaging studies stored on a Visage 7 server. The company provides its products under the Visage RIS, Visage RIS/PACS, Visage 7, Visage Ease Pro, and Visage Ease names. Pro Medicus Limited was incorporated in 1983 and is headquartered in Richmond, Australia.
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | 2016‑06 | |
Income | |||||||||
Revenues | 161,429 29.25% | 124,900 33.64% | |||||||
Cost of revenue | 72,466 | 44,313 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | 88,963 | 80,587 | |||||||
NOPBT Margin | 55.11% | 64.52% | |||||||
Operating Taxes | 33,704 | 25,478 | |||||||
Tax Rate | 37.89% | 31.62% | |||||||
NOPAT | 55,259 | 55,109 | |||||||
Net income | 82,794 36.52% | 60,648 36.47% | |||||||
Dividends | (36,554) | (26,108) | |||||||
Dividend yield | 0.24% | 0.38% | |||||||
Proceeds from repurchase of equity | (2,769) | (845) | |||||||
BB yield | 0.02% | 0.01% | |||||||
Debt | |||||||||
Debt current | 553 | 1,425 | |||||||
Long-term debt | 3,585 | 2,394 | |||||||
Deferred revenue | 25,850 | 23,421 | |||||||
Other long-term liabilities | 113 | 77 | |||||||
Net debt | (162,479) | (120,037) | |||||||
Cash flow | |||||||||
Cash from operating activities | 86,776 | 64,773 | |||||||
CAPEX | (6,693) | (6,446) | |||||||
Cash from investing activities | (78,074) | (9,795) | |||||||
Cash from financing activities | (39,841) | (27,527) | |||||||
FCF | 54,168 | 39,901 | |||||||
Balance | |||||||||
Cash | 155,425 | 121,495 | |||||||
Long term investments | 11,192 | 2,361 | |||||||
Excess cash | 158,546 | 117,611 | |||||||
Stockholders' equity | 187,728 | 138,776 | |||||||
Invested Capital | 57,214 | 46,514 | |||||||
ROIC | 106.55% | 145.84% | |||||||
ROCE | 39.82% | 46.87% | |||||||
EV | |||||||||
Common stock shares outstanding | 104,652 | 104,588 | |||||||
Price | 143.26 118.25% | 65.64 55.36% | |||||||
Market cap | 14,992,499 118.39% | 6,865,133 55.37% | |||||||
EV | 14,830,020 | 6,745,096 | |||||||
EBITDA | 97,473 | 88,513 | |||||||
EV/EBITDA | 152.14 | 76.20 | |||||||
Interest | |||||||||
Interest/NOPBT |